Recent Advance of Enzyme Targets for the Management of Vascular Dementia

Abstract

The basic understanding of vascular dementia (VaD) and their molecular mechanisms are a too complex phenomenon. VaD associated neurodegeneration and cognitive impairment are due to multiple complications of the neurovascular system. The progress of VaD is due to the central and/or peripheral pathophysiological process of the neurovascular system. There are limited nootropic agents are employed for the treatment of VaD. Moreover, the explored nootropic agents act on multiple targets such as receptors, enzymes, ion channel, free radicals, cytokines, chemokines, and apoptotic proteins. However, the enzyme targets, especially acetylcholinesterase inhibitors played a crucial role in the management of cognitive disorders. The pathogenesis of VaD is involved in the vascular complication and neurodegenerative process. Hence, the enzymatic regulation of neurovascular complication is expected to prevent the VaD. The present chapter attempts to explore the recent advancement of enzyme targets for the management of VaD.

Donepezil down‐regulates propionylation, 2‐hydroxyisobutyrylation, butyrylation, succinylation, and crotonylation in the brain of bilateral common carotid artery occlusion‐induced vascular dementia rats

“…In previous studies, limited nootropic agents have been used for the treatment of VaD, which have been identified to play a role in the regulation of multiple targets, including receptors, enzymes, ion channels, free radicals, cytokines, chemokines, and apoptotic proteins 10 . Among the various nootropic agents, acetylcholinesterase inhibitors have proven to be efficient therapeutic agents in the management of cognitive impairment 11 .…”